Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (28421)	2/27/1999 11:27:00 PM
From: Cheryl Galt	Respond to of 32384

Henry, neither have I. Besides the FDA site, I've searched the 1997 annual report, the 3Q SEC report, the 2Q, and many press releases, and have come up with zip. I can find nothing in print that says Targretin has orphan designation for CTCL. (Found Nipent -- Pentostatin -- though.) We've talked so much about it, that I'm shocked that I have no documentation. I'm sure this is just a loose end. Still, someone out there, please supply a link, or tell us when it was announced. I've been wondering why there's been no NDA application filed yet for Targretin/CTCL. For Ligand's financial health, this event is on the critical path. Cheryl ----------------------------------------- By the way, newer Ligand press releases are at business wire businesswire.com Older ones (Aug 1996 - June 1998) are at pr newswire prnewswire.com Here's a more direct route to the FDA's Orphan designates fda.gov